Clever Culture Systems (ASX:CC5) said it received a second purchase order from an additional Bristol Myers Squibb facility for its Automated Plate Assessment System Independence technology, which is expected to form a case study for the potential roll out to other Bristol Myers Squibb sites, according to a Wednesday Australian bourse filing.

It said that the sales pipeline for the pharmaceutical industry consisted of over 40 active and qualified customer opportunities, representing an estimated AU$75 million in potential upfront sales revenue and AU$15 million per annum in recurring revenue.

A multinational pharmaceutical firm is evaluating its technology, which automates the imaging, analysis, and interpretation of microbiology culture plates, covering over 6,000 plates, with the resulting data currently being compiled. The evaluation assessed the performance of the settle plate analysis module and is being extended to the contact plate analysis module.

Its shares jumped 6% on market close on Thursday.